Welcome to our dedicated page for Acurx Pharmaceuticals SEC filings (Ticker: ACXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acurx Pharmaceuticals, Inc.'s SEC filings document a late-stage biopharmaceutical issuer developing antibiotics for difficult-to-treat Gram-positive bacterial infections. Registration statements describe securities offerings, resale registration mechanics, common stock, warrants and the company's status as an emerging growth company and smaller reporting company.
ACXP's Form 8-K filings record material events tied to capital structure, governance and compensation, including amendments to authorized common shares and executive and director compensation arrangements. The filings also cover Nasdaq-listed common stock, operating and financial results, material agreements, shareholder voting matters and risk disclosures associated with antibiotic research and development.
Acurx Pharmaceuticals, Inc. is registering 750,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under an existing equity purchase agreement. These shares are "Purchase Shares" that have been or may be issued to Lincoln Park under a $12.0 million commitment.
The company is not selling any shares in this prospectus and will not receive proceeds from Lincoln Park’s resales. However, Acurx may still receive up to $7.6 million in gross proceeds from future direct sales of common stock to Lincoln Park under the Purchase Agreement, separate from this resale.
As of January 30, 2026, Acurx had 2,546,717 common shares outstanding. If all 750,000 registered shares were issued, they would represent about 23% of total shares and about 24% of shares held by non-affiliates, increasing dilution for existing stockholders.
Acurx Pharmaceuticals (ACXP) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $1,992,790 and a nine‑month net loss of $6,388,262. Cash was $5,906,802 as of September 30, 2025, with total assets of $6,105,211, liabilities of $2,468,175, and shareholders’ equity of $3,637,036. Operating expenses fell year over year, led by lower R&D ($429,691 vs. $1,198,184 in Q3 2024).
The company completed multiple financings in 2025: a January registered direct offering ($2.5M gross), a March registered direct offering with pre‑funded warrants ($1.1M gross), an equity line of credit with Lincoln Park of up to $12.0M (393,532 shares sold for $2.4M gross through Q3), and a June warrant‑inducement exercise yielding ~$2.5M net. Subsequent to quarter‑end, $1.4M was received from warrant exercises, and total ELOC sales reached 499,999 shares for ~$3.0M gross through November 11, 2025.
The company effected a 1‑for‑20 reverse stock split on August 4, 2025 and increased authorized common shares to 250,000,000 in September. Management disclosed “substantial doubt” about the ability to continue as a going concern. Shares outstanding were 1,800,299 as of September 30, 2025 and 2,085,363 as of November 11, 2025.
Acurx Pharmaceuticals filed a resale prospectus for up to 585,000 shares of common stock to be sold from time to time by Lincoln Park Capital under an existing purchase agreement. The company is not selling any securities in this prospectus and will not receive proceeds from sales by the selling stockholder.
Under the Purchase Agreement, Acurx may sell additional shares to Lincoln Park at its discretion, from which the company may receive up to $9.0 million in aggregate gross proceeds (in addition to $3.0 million previously received), subject to terms and conditions. The selling stockholder is deemed an underwriter, and Acurx will cover registration expenses other than brokerage fees.
A 1-for-20 reverse stock split became effective on August 4, 2025. As of October 14, 2025, 2,081,323 shares were outstanding. If all 585,000 shares registered here were issued and outstanding as of that date, they would represent approximately 22% of total shares outstanding. A 4.99% Beneficial Ownership Cap applies to Lincoln Park, which may be increased to 9.99% upon notice and after 61 days.
Acurx Pharmaceuticals (ACXP) filed an S‑1 to register up to 585,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC. The company is not selling any securities in this prospectus and will not receive proceeds from the selling stockholder’s sales.
These shares relate to Acurx’s May 8, 2025 Purchase Agreement with Lincoln Park. Separately from this resale, Acurx may sell additional shares to Lincoln Park at its discretion and could receive up to $9.0 million in aggregate gross proceeds (in addition to $3.0 million previously received) after the May 29, 2025 commencement, subject to conditions. Regular purchases are priced at 97% of the lower of the day’s lowest sale price or the average of the three lowest closes in the prior 10 business days, with per‑day share and $500,000 per‑purchase caps and optional accelerated purchases. A 4.99% Beneficial Ownership Cap applies, which Lincoln Park may increase to 9.99% with 61 days’ notice. Shares outstanding were 2,081,323 as of October 14, 2025. A 1‑for‑20 reverse stock split became effective on August 4, 2025.
Acurx Pharmaceuticals, Inc. filed a Form 8-K dated September 22, 2025 reporting a material event: the company attached a Certificate of Amendment to the Certificate of Incorporation that is dated September 19, 2025. The filing notes inclusion of the cover page Inline XBRL tags and is signed by David P. Luci, President and Chief Executive Officer. The report appears limited to the corporate charter amendment and related filing mechanics; no financial statements, earnings data, or transaction details are included in the provided text.
Acurx Pharmaceuticals, Inc. filed a Form 8-K dated September 22, 2025 reporting a material event: the company attached a Certificate of Amendment to the Certificate of Incorporation that is dated September 19, 2025. The filing notes inclusion of the cover page Inline XBRL tags and is signed by David P. Luci, President and Chief Executive Officer. The report appears limited to the corporate charter amendment and related filing mechanics; no financial statements, earnings data, or transaction details are included in the provided text.
Acurx Pharmaceuticals, Inc. stockholders approved several key items at a special meeting held on September 16, 2025. Of 30,524,540 common shares outstanding as of the July 21, 2025 record date, 19,365,579 shares, or about 63.44%, were represented, establishing a quorum. Stockholders approved, for Nasdaq Listing Rule 5635(d) purposes, issuing common shares underlying Series G-2 warrants that could equal 20% or more of common stock outstanding before those warrants were issued. They also approved increasing authorized common shares from 200,000,000 to 250,000,000, subject to the board’s discretion, and approved the potential adjournment of the meeting to solicit additional proxies if needed.
Acurx Pharmaceuticals, Inc. stockholders approved several key items at a special meeting held on September 16, 2025. Of 30,524,540 common shares outstanding as of the July 21, 2025 record date, 19,365,579 shares, or about 63.44%, were represented, establishing a quorum. Stockholders approved, for Nasdaq Listing Rule 5635(d) purposes, issuing common shares underlying Series G-2 warrants that could equal 20% or more of common stock outstanding before those warrants were issued. They also approved increasing authorized common shares from 200,000,000 to 250,000,000, subject to the board’s discretion, and approved the potential adjournment of the meeting to solicit additional proxies if needed.
Armistice Capital and Steven Boyd report passive ownership of 8.70% of Acurx Pharmaceuticals common stock. The filing states Armistice Capital, as investment manager of Armistice Capital Master Fund Ltd., and Steven Boyd, as managing member, share voting and dispositive power over 2,917,975 shares. The Master Fund is the direct holder while Armistice Capital exercises investment and voting power under an Investment Management Agreement; the Master Fund disclaims beneficial ownership arising solely from that agreement. The filing is made on Schedule 13G indicating the holdings are reported as passive.
Acurx Pharmaceuticals (ACXP) reported $6.06 million in cash and total assets of $6.16 million at June 30, 2025, up from $3.71 million and $3.86 million at December 31, 2024, respectively. The company incurred a net loss of $2.25 million for the three months ended June 30, 2025 and $4.40 million for the six months ended June 30, 2025, which are both smaller than the comparable 2024 periods. Research and development expense declined to $524,210 in the quarter, reducing total operating expenses to $2.27 million.
Cash used in operating activities for the six months was $3.72 million while financings provided $6.08 million of net cash in the period, including registered offerings, an equity line of credit and a warrant inducement. Management warns that as of June 30, 2025 the Company believed its cash was insufficient to meet anticipated cash requirements for at least 12 months, raising substantial doubt about its ability to continue as a going concern. The filing also discloses Nasdaq notices for minimum stockholders' equity and minimum bid price noncompliance and a 1-for-20 reverse stock split effected in August 2025.
Acurx Pharmaceuticals’ September 16, 2025 virtual special meeting asks holders to approve three items:(1) under Nasdaq Rule 5635(d) the potential issuance of up to 133,363 new shares (≥20% of current float) upon exercise of Series G-2 warrants created in a June 17, 2025 warrant-inducement financing;(2) an amendment increasing authorized common shares to 250 million from 200 million; and(3) authority to adjourn the meeting if needed.
The June financing exchanged 222,272 previously outstanding warrants (cash-exercised at $12.00) for (i) 311,180 Series G-1 and (ii) 133,363 Series G-2 warrants, both exercisable at $8.50. The transaction delivered $2.67 million gross proceeds and could yield a further ≈$1.1 million if the G-2 warrants are cash-exercised after shareholder approval. A one-for-20 reverse split became effective August 4, 2025, shrinking outstanding shares to 1,526,227 as of the July 21 record date.
Failure to approve Proposal 1 renders the G-2 warrants non-exercisable and obligates the board to hold successive 90-day meetings until approval, while also forfeiting potential proceeds. Proposal 2 is framed as providing capital-raising flexibility; current fully diluted commitments leave ~197 million authorized shares unused. Management and directors own 20.3% of shares; Armistice Capital is the only 5%+ holder at 24.6%. Cash on hand was $4.6 million at March 31 2025.